Metformin, which belongs to the biguanide class of antidiabetics, works by decreasing glucose production in the liver, slowing down glucose absorption in the intestines, and improving insulin sensitivity. On the other hand, Linagliptin, a DPP-4 inhibitor, increases insulin release from the pancreas and lowers the levels of hormones that elevate blood sugar.